Clinical Trial Update: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating ENCIT-01, an engineered neuroblastoma cellular immunotherapy, in patients with neuroblastoma or ganglioneuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ganglioneuroblastoma
• Neuroblastoma

Drugs mentioned

• ENCIT-01

Snippet

Sponsor: Seattle Children's Hospital | Conditions: Neuroblastoma, Ganglioneuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING